Companies / Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

Nasdaq: ALLOCIK 1737287SOUTH SAN FRANCISCO, CA

Financials · FY2025

Revenue$0
Net income$-190.89M
Total debt—
Cash$38.63M
Diluted EPS$-0.87
Shares outstanding345.5M

Ownership

345.5M shares outstanding · as of Aug 10, 2026
2.1%Insiders
Ownership
Insiders2.14%7,383,023
10%+ / strategic5.51%19,025,826
Institutions53.05%183,282,564
Public float39.31%135,799,468

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
David D. Chang, M.D., Ph.D.CEOPresident and CEO · Director
1.49%5,150,599
Parker Geoffrey M.CHIEF FINANCIAL OFFICER
0.36%1,252,795
Roberts ZacharyEVP of R&D
0.17%581,166
Douglas Earl MartinFormerSVP, General Counsel
0.16%564,948
Kazam Joshua ADirector
0.12%398,463
Beneski Benjamin MachinasFormerSVP, Chief Technical Officer
0.06%198,205
Yoshiyama AnnieFormerSVP, Finance
0.04%130,322
Arie Belldegrun, M.D.Director
——
Sato Vicki LDirector
——

Institutional holders 179

View all →
HolderValue% of shares
BlackRock, Inc.$62.71M8.73%
State Street Corporation$39.57M5.51%
Pfizer Inc$30.18M6.38%
Tpg Gp a, LLC$25.64M5.42%
Citadel Advisors LLC$16.59M3.51%
Two Sigma Investments, LP$13.12M1.56%
Vanguard Group Inc$12.67M2.68%
Primecap Management CO/CA$11.15M2.36%
Geode Capital Management, LLC$10.07M1.19%
Marshall Wace, LLP$8.41M1.00%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 2, 2026David D. Chang, M.D., Ph.D.
CEO
SellCommon Stock$171.5K-95K
-1.80%
5,185,862
1.50% of shares
medium
Mar 16, 2026David D. Chang, M.D., Ph.D.
CEO
SellCommon Stock$118.0K-48K
-0.92%
5,150,599
1.49% of shares
medium
Feb 2, 2026Roberts Zachary
Executive
SellCommon Stock$63.2K-36K
-5.79%
581,166
0.17% of shares
low
Feb 2, 2026Parker Geoffrey M.
Executive
SellCommon Stock$42.2K-24K
-1.88%
1,252,795
0.36% of shares
low
Jan 21, 2026Roberts Zachary
Executive
SellCommon Stock$41.0K-26K
-4.08%
616,866
0.18% of shares
low
Feb 2, 2026Douglas Earl Martin
Executive
SellCommon Stock$40.3K-23K
-3.90%
564,948
0.16% of shares
low
Mar 2, 2026Beneski Benjamin Machinas
Executive
SellCommon Stock$18.5K-7K
-3.39%
203,040
0.06% of shares
low
Feb 2, 2026Beneski Benjamin Machinas
Executive
SellCommon Stock$13.1K-8K
-3.47%
210,172
0.06% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Arie Belldegrun, M.D.Passive13G/A———
State Street CorporationPassive13G—19,025,826—
Arie Belldegrun, M.D.Passive13G/A———
David D. Chang, M.D., Ph.D.Passive13G———
Arie Belldegrun, M.D.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ALLO——019770106—